Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-16

Clinical Trial Update: Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures [Phase 3]

View source ↗

Summary

Phase 3 trial update on eslicarbazepine acetate as monotherapy for newly diagnosed partial-onset seizures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 3 | Status: COMPLETED